Aurobindo Pharma Limited has informed the Exchange about classification of US FDA Inspection at Unit-I of Apitoria Pharma Private Limited as VAI
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has informed the exchange that the US FDA has classified its recent inspection of Unit-I belonging to Apitoria Pharma Private Limited (a subsidiary) as VAI — Voluntary Action Indicated. This is the most favourable classification, meaning the FDA found no significant violations and no mandatory corrective action is required. The unit can continue normal operations and supply to the US market without restrictions. This removes any regulatory overhang on this particular facility and supports continued exports.
Positive for shareholders — clears regulatory uncertainty around this unit and supports uninterrupted US sales, which is a key revenue market for Aurobindo. Likely to be viewed favourably by the market.